Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
ConditionHypertension
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19-64
SponsorAddpharma Inc.
About this trial
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Healthy adult volunteers aged ≥19 and <65 years at the time of the screening visit
Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit
Disqualifiers
Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
Other exclusions applied
Trial design
Design model
Parallel
Treatments tested in this trial
Treatment A(AD-2321)
DrugAD-2321 Oral Tablet
Treatment B(AD-2322)
DrugAD-2322 Oral Tablet
Treatment C(AD-2321+AD-2322)
DrugAD-2321 Oral Tablet+AD-2322 Oral Tablet
Treatment groups
41 Participants
are divided into 2 treatment groupsGroup A: Arm AExperimental treatment 2 interventions
Group B: Arm BExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss)
AUCτ,ss
Time frame
pre-dose (0hour) to 24 hours post-dose on Day 142
Maximum concentration of drug in plasma at steady state (Cmax,ss)
Time frame
pre-dose (0hour) to 24 hours post-dose on Day 14Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: